2022
Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI.
Borde T, Nezami N, Laage Gaupp F, Savic LJ, Taddei T, Jaffe A, Strazzabosco M, Lin M, Duran R, Georgiades C, Hong K, Chapiro J. Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI. Radiology 2022, 304: 228-237. PMID: 35412368, PMCID: PMC9270683, DOI: 10.1148/radiol.212426.Peer-Reviewed Original ResearchConceptsMedian overall survivalAdvanced-stage hepatocellular carcinomaTransarterial chemoembolizationHepatocellular carcinomaBCLC BBCLC COverall survivalTumor burdenBarcelona Clinic Liver Cancer (BCLC) staging systemLiver Cancer staging systemCancer (AJCC) staging systemConventional transarterial chemoembolizationDrug-eluting beadsAllocation of patientsContrast-enhanced MRIBackground PatientsSurvival benefitRetrospective studyStaging systemC tumorsTumor volumePatientsHeterogeneous patientsMonthsChemoembolization
2019
The impact of socioeconomic status on outcomes in hepatocellular carcinoma: Inferences from primary insurance
Sellers CM, Uhlig J, Ludwig JM, Taddei T, Stein SM, Lim JK, Kim HS. The impact of socioeconomic status on outcomes in hepatocellular carcinoma: Inferences from primary insurance. Cancer Medicine 2019, 8: 5948-5958. PMID: 31436905, PMCID: PMC6792508, DOI: 10.1002/cam4.2251.Peer-Reviewed Original ResearchConceptsHepatocellular carcinomaPrivate insuranceInsurance statusMedicaid patientsCox proportional hazards modelAdvanced liver diseaseChild-Pugh BHigh MELD scoreAmerican Joint CommitteeKaplan-Meier curvesProportional hazards modelInsurance groupsMELD scoreOverall survivalIndependent predictorsLiver diseaseMultivariable analysisTumor burdenCancer RegistryTumor sizePotential confoundersSurvival differencesCancer stageUnivariate analysisC diseaseSystemic Management for Advanced Hepatocellular Carcinoma: A Review of the Molecular Pathways of Carcinogenesis, Current and Emerging Therapies, and Novel Treatment Strategies
Saffo S, Taddei TH. Systemic Management for Advanced Hepatocellular Carcinoma: A Review of the Molecular Pathways of Carcinogenesis, Current and Emerging Therapies, and Novel Treatment Strategies. Digestive Diseases And Sciences 2019, 64: 1016-1029. PMID: 30887150, DOI: 10.1007/s10620-019-05582-x.BooksConceptsAdvanced hepatocellular carcinomaHepatocellular carcinomaTreatment strategiesMulti-targeted tyrosine kinase inhibitorSystemic managementGeneral host factorsEffective systemic therapyInitial treatment strategyMulti-modal therapyOverall tumor burdenCancer-related deathNovel treatment strategiesTyrosine kinase inhibitorsDifferent treatment classesKey molecular targetsInoperable diseaseCheckpoint inhibitorsEmerging TherapiesMost patientsDurable cureSystemic therapyLandmark trialsTumor burdenTelomerase reverse transcriptaseTherapy
2017
Association of change in AFP > 15 ng/ml/month with stage at diagnosis and mortality in patients with hepatocellular carcinoma (HCC).
Ilagan-Ying Y, Kaplan D, Taddei T, Njei B. Association of change in AFP > 15 ng/ml/month with stage at diagnosis and mortality in patients with hepatocellular carcinoma (HCC). Journal Of Clinical Oncology 2017, 35: 255-255. DOI: 10.1200/jco.2017.35.4_suppl.255.Peer-Reviewed Original ResearchHepatocellular carcinomaCause mortalityVeterans Administration Corporate Data WarehouseStage of HCCBCLC stage BBCLC stage DLiver disease severityAdvanced-stage cancerUseful prognostic markerAssociation of changesDate of deathLogistic regression analysisPotential hepatocellular carcinomaManual chart abstractionRegression analysisCorporate Data WarehouseChart abstractionBCLC 0Tumor burdenLiver diseaseTumor stagingUS veteransPrognostic markerHCC casesDiagnostic confirmation